Experimental combo aims to boost stem cell transplant for rare blood cancers
NCT ID NCT02512497
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested whether adding the drug romidepsin before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Twenty-three patients received romidepsin along with standard chemotherapy, followed by a donor stem cell transplant. The main goals were to find the safest dose and see if the approach helped patients engraft and survive at least 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Romidepsin (also known as Istodax)
- What this could lead to
- If this works, it could point toward a safer and more effective way to use stem cell transplants for T-cell cancers, potentially improving long-term control of the disease.
- What could go wrong
- This is a very early phase 1 trial with only 23 participants, so the results are preliminary. The combination may cause serious side effects, and it is not yet known if it truly improves outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Ohio State University Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a Five-Drug combo tame a tough lymphoma without standard chemo?
- Can a targeted pill boost Chemotherapy's punch against a rare lymphoma?
- A microchip implanted in tumors could reveal which drugs work best
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Skin gel targets immune signals in rare lymphoma